From START to Finish: National and International Perspectives on Disseminating Research to Practice for the Treatment of Opioid Dependence.
Andrew J. Saxon, MD (VA Puget Sound Health Care System, PN Node), George Woody, MD (University of Pennsylvania, DV Node), Petra Jacobs, MD (NIDA Center for the Clinical Trials Network), Richard Crist, PhD (University of Pennsylvania, DV Node), Adhi Wibowo Nurhidayat, MD (Jakarta Project, Indonesia), Mathew Hickman, PhD (University of Bristol, UK), John Strang, MD (Kings College, London, UK).
Workshop sponsored by the National Institute on Drug Abuse (NIDA), the National Drug Abuse Treatment Clinical Trials Network (CTN), and the NIDA/SAMHSA Blending Initiative in collaboration with the American Association for the Treatment of Opioid Dependence (AATOD), Philadelphia, PA, November 10, 2013
This segment of the session presented several important secondary outcomes from the START study including:From a comparison of the impact of MET vs. BUP/Nx treatment on HIV risk behaviors; a description of six different BUP/Nx and three different MET induction trajectories and their outcomes; and an association between genotype and treatment outcome in African-American participants receiving BUP/Nx or MET.
Session Two: International Perspective
To complement the findings and dissemination strategies from the U.S. perspective, a panel of international collaborators presented findings from studies conducted abroad and implementation strategies that have been successful. Presentations included outcomes from a collaborative project between NIDA and treatment providers in Indonesia, data from epidemiological studies showing the association between the length of MET treatment and mortality rates and dissemination and implementation strategies, and the use of incentive-based interventions in reducing drug use and associated consequences. The session also described the N-ALIVE (NALoxone InVEstigation) study--a large, prison-based, trial that assesses the number of lives that could be saved by providing Naloxone-on-release to adult prisoners with a history of heroin injection. The discussion after session two focused on on how the knowledge gained from these analyses and findings can be translated for the implementation of relevant MET or BUP/Nx treatment in clinical settings treating opioid dependent patients in the U.S. as well as internationally